Medtronic (MDT) stock popped Tuesday as its diabetes spinoff Minimed (MMED) rallied, reversing premarket losses, after both lifted their full-year guidance. Medtronic posted organic sales growth of 13.7%, roughly 200 basis points above the midpoint of its guidance, Evercore ISI analyst Vijay Kumar said in a report. Importantly, cardiovascular and medical-surgical sales all topped forecasts, but neuroscience coming in line.…
Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
